stockrowKiniksa Pharmaceuticals International, plc
KNSA Healthcare Drug Manufacturers Specialty & Generic
Kiniksa Pharmaceuticals International, plc’s revenue for fiscal 2025 (year ended December 2025) was $677.6 million, up 60.1% from fiscal 2024.
- Revenue
- +58.1%
- EPS
- +142.2%
- Free cash flow
- +43.5%
Quarter to September 2026, against a year earlier
Follow KNSA
Alert me
Kiniksa Pharmaceuticals International, plc (KNSA) Revenue growth
Kiniksa Pharmaceuticals International, plc's revenue growth over the twelve months to 30 September 2026 was 58.2%, down 1.9 percentage points from fiscal 2025 (60.1%). That is above the Drug Manufacturers Specialty & Generic industry median of 5.22% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 60.1% | 3.49 |
| FY2024 | 56.6% | 33.86 |
| FY2023 | 22.7% | (448.50) |
| FY2022 | 471.2% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 58.1% | 2.76 |
| Jun 2026 | 55.4% | (0.15) |
| Mar 2026 | 55.5% | (9.44) |
| Dec 2025 | 65.0% | 3.78 |
| 14 more quarters | Free account |
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| LQDA Liquidia Corporation compare | 2,233.7% |
| KNSA Kiniksa Pharmaceuticals International, plc | 58.2% |
| HIMS Hims & Hers Health, Inc. compare | 28.0% |
| SUPN Indivior Pharmaceuticals Inc. compare | 16.4% |
| ALKS Alkermes plc compare | 15.3% |
| ELAN Elanco Animal Health Incorporated compare | 12.0% |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | 8.88% |
| LNTH Lantheus Holdings, Inc. compare | 2.38% |
| RDY Dr. Reddy's Laboratories Ltd compare | −15.5% |
| Drug Manufacturers Specialty & Generic industry median | 5.22% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on KNSA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement